MENLO PARK, Calif.,
Sept. 5, 2017 /PRNewswire/
-- BioPharmX Corporation (NYSE MKT: BPMX), a specialty
pharmaceutical company developing products for the dermatology
market, today announced that Anja
Krammer, president and co-founder of BioPharmX, will present
at the Rodman & Renshaw 19th Annual Global
Investment Conference next week.
Ms. Krammer is scheduled to present on September 12 from 3:25 – 3:50 p.m. EDT in the Louis Room at the Lotte New
York Palace Hotel. A live webcast of the presentation will be
available at
http://www.wsw.com/webcast/rrshq27/bpmx and will be archived for 90
days following the presentation.
The Rodman & Renshaw 19th Annual Global
Investment Conference hosts approximately 200 public and private
companies presenting to an audience of approximately 2,000
attendees. The conference focuses on tracks dedicated to
healthcare, natural resources, technology, media and
telecommunications, and cleantech.
About BioPharmX® Corporation
BioPharmX
Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty
pharmaceutical company, which seeks to provide products through
proprietary platform technologies for prescription,
over-the-counter (OTC), and supplement applications in the health
and wellness markets, including dermatology and women's health. To
learn more about BioPharmX, visit www.BioPharmX.com.
Forward-Looking Statements
The information in this
press release contains forward-looking statements and information
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the "safe harbor" created by those
sections. This press release contains forward-looking statements
about the company's expectations, plans, intentions, and
strategies, including, but not limited to, statements regarding the
safety and medical effects of BPX-01, the effect BPX-01 may have on
the treatment of acne, the commencement and results of future
trials of BPX-01 and the size of such trials, continued and
consistent results in future tests of BPX-01 and absence of side
effects of future use of BPX-01. These forward-looking statements
may be identified by words such as "plan," "expect," "anticipate,"
"believe" or similar expressions that are intended to identify such
forward-looking statements.
These forward-looking statements involve risks and
uncertainties, as well as assumptions, which, if they do not fully
materialize or prove incorrect, could cause our results to differ
materially from those expressed or implied by such forward-looking
statements. The risks and uncertainties include those described in
the company's filings with the Securities and Exchange Commission,
including our annual report on Form 10-K for the period
ended Jan. 31, 2017 and our quarterly report on Form 10-Q for
the period ended April 30, 2017.
Given these risks and uncertainties, you are cautioned not to place
undue reliance on such forward-looking statements. The
forward-looking statements included in this news release are made
only as of the date hereof, and the company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as may be required under applicable securities
law.
BioPharmX is a registered trademark of BioPharmX, Inc.
View original content with
multimedia:http://www.prnewswire.com/news-releases/biopharmx-to-present-at-rodman--renshaw-19th-annual-global-investment-conference-300511818.html
SOURCE BioPharmX Corporation